Clinical Trials Directory

Trials / Completed

CompletedNCT02658851

Cold Plasma for the Reduction of Lymphoceles Following PLND

Application of Cold Plasma Energy for Reduction of Lymphoceles Following Pelvic Lymph Node Dissection During Robot-Assisted Radical Prostatectomy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Apyx Medical · Industry
Sex
Male
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study protocol will evaluate the efficacy of Bovie Medical's J-Plasma® helium based plasma technology in the reduction of lymphoceles following pelvic lymph node dissection (PLND) during robotic assisted radical prostatectomy (RARP). The J-Plasma® handpiece will be used during the PLND by dissecting the lymph nodes and sealing the lymphatic channels to prevent lymph leakage.

Detailed description

Participants evaluated and scheduled for a PLND during Robotic Assisted Radical Prostatectomy who have met the study inclusion criteria and who have also given informed consent will be enrolled. Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels. An abdominal-pelvic ultrasound will be completed at a follow-up period ranging from 4-12 weeks post operatively to determine if a lymphocele is present. The occurrence rate of lymphoceles in this trial group will be compared to retrospective data from the principal investigator's practice and other published data to determine if the occurrence rate has been reduced.

Conditions

Interventions

TypeNameDescription
DEVICEJ-PlasmaBovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.

Timeline

Start date
2016-06-01
Primary completion
2017-06-27
Completion
2017-06-27
First posted
2016-01-20
Last updated
2020-12-02
Results posted
2020-12-02

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT02658851. Inclusion in this directory is not an endorsement.